REG - RTW Biotech Opp. - Appointment of Senior Independent Director

RTW Biotech OpportunitiesAnnouncement

10/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241210:nRSJ4808Pa&default-theme=true

RNS Number : 4808P  RTW Biotech Opportunities Ltd  10 December 2024

LEI: 549300Q7EXQQH6KF7Z84

10 December 2024

RTW Biotech Opportunities Ltd
(the "Company")

Appointment of Senior Independent Director

 

The Company is pleased to announce that Baroness Nicola Blackwood has been
appointed as Senior Independent Non-Executive Director with effect from 9
December 2024.

For Further Information:

 

 RTW Investments, LP                           +44 (0)20 7959 6361
 Woody Stileman, Managing Director

 Krisha McCune, Director, Investor Relations

 

About Baroness Nicola Blackwood

Nicola was appointed to the board of the Company on 11(th) July 2024.  She is
a leader in science and entrepreneurship. She is a member of the House of
Lords, and Chair of Genomics England and Oxford University Innovation. Since
2023, she has been a Supervisory Board member of the biotechnology company,
BioNTech. Nicola served as Minister for Innovation in the Department for
Health and Social Care under two Prime Ministers where she led on
Lifesciences, NHS Data and Digital Transformation, and Global Health Security.
She was the first female MP for Oxford and was elected by MPs of all parties
to Chair the Commons Science and Tech Committee. She remains one of the
youngest committee chairs in British history and the only woman to have
chaired the Commons Science & Tech Committee.

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on
identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGPGMPPUPCUQU